Gilead's Latest Deal Shows Big Pharma's Appetite for Oral Peptides. Which Stocks Are Worth Watching?

Gilead Sciences' $1.275 billion upfront investment in an oral peptide program from PepStar Therapeutics highlights growing big pharma interest in oral peptide therapies, even at early development stages. This puts a spotlight on companies like Entera Bio, which is advancing its oral peptide EB613 for osteoporosis into Phase 3 with promising patient efficacy data and secured funding. The article suggests that Entera's N-Tab platform, designed to enable oral delivery of complex peptides, could unlock broader markets for bone-building treatments and other conditions.